Droplet capture device based on coherent light imaging and rapid screening method for viral nucleic acid

Abstract

The present invention discloses a droplet capture device based on coherent light imaging and a rapid screening method for viral nucleic acid. The droplet capture device includes a protective mask, which is worn on the face of a person being tested; it also includes a capture box used in conjunction with the protective mask, which is movably mounted on the protective mask; a capture body is provided on one side of the capture box, and the capture box and the capture body are in a right-facing T-shape; the capture body is a cavity with an opening on one side, and a capture sheet is vertically provided in the cavity; the person being tested wears the droplet capture device, the capture body is combined with the mouth of the person being tested, and the person being tested speaks or exhales, and the capture sheet captures the droplets in the mouth of the person being tested. The capture sheet is based on a polyimide film, and a plurality of pits are pressed on the capture sheet by molding. The present invention has a simple and reasonable structure, and is used to conveniently and quickly capture the droplets of the person being tested on a large scale, and is used for the initial screening of patients with new coronavirus; the cost is not high, and it is conducive to large-scale promotion and use.

Description

Technical Field

[0001] The present invention relates to the technical field of virus nucleic acid matching and screening, and in particular to a droplet capturing device based on coherent light imaging and a method for rapid screening of virus nucleic acid. Background Art

[0002] Currently, the detection of coronavirus is based on the PCR method, that is, the viral nucleic acid (RNA) amplification fluorescence detection method), which is characterized by the principle of introducing fluorescent groups through gene breaks and reproducing the luminescence of DNA fluorescent groups. By detecting the fluorescence intensity during the amplification period, the statistical counting of the baseline RNA is achieved to determine the virus content.

[0003] Since the preparation of specific gene fragments is very cumbersome and requires a long and complex process of decomposition, extraction, and preservation, it places very high demands on the testing environment, equipment, and professional level of personnel. Although the accuracy is very high, the above strict technical requirements are doomed to be inefficient and expensive in large-scale clinical rapid and low-cost screening.

[0004] In view of the rapid spread of coronavirus, the current PCR method is used for positive screening of key populations, and the record is that it takes 30 minutes to confirm. Assuming that a PCR laboratory has 50 groups of people doing tests at the same time (current conditions are almost unattainable), 50 people's samples can be measured every 30 minutes, and 10 hours of work per day, 50*10*2=1000 people; on this basis, 10 laboratories with the same conditions are set up in key epidemic areas, and 10,000 people's samples can be tested every day. Assuming that 1 million people in key epidemic areas are to be screened with key nucleic acid reagents, the time to complete a screening is 1000000 / 10000=100 days. The onset period of coronavirus is 0-24 days, calculated based on the median time of 3 days. Assuming that 100 people randomly develop the disease in these 100 days, statistically speaking, nucleic acid testing cannot detect most of these 100 people in advance. Therefore, nucleic acid reagent detection can only be used for the detection of characteristic models (targeted very small number of suspected patients), and cannot be used for large-scale preventive screening mechanisms.

[0005] Figure 1 This is the layout of a traditional PCR laboratory (not including the sample collection area). The high environmental requirements for PCR testing bring difficulties to application:

[0006] 1. The test kit needs to be transported via cold chain. According to the prescribed procedures, the test kit will generally be sent to the provincial CDC and then distributed by the provincial CDC.

[0007] 2. At the same time, the use of test kits for testing has a high threshold and requires the use of relevant laboratories, instruments and technicians. This has brought delays and difficulties to the application of test kits.

[0008] 3. The testing laboratory needs to be strictly divided. The basic settings are: sample receiving area, reagent preparation area, specimen preparation area, amplification and testing area. After each room is completed, it will pass through the transfer window to the next room. The first room receives the sample; the second room is for reagent preparation; the third room extracts nucleic acid; and the last room is for PCR technology amplification and detection analysis.

[0009] 4. When testing for viruses, it is not ruled out that there are live virus particles in the sample, especially highly infectious or unknown new viruses, which require a special negative pressure environment to prevent viral infection. To avoid contamination, the test must be done in a laboratory that meets at least biosafety level 2. The testing laboratory must have negative pressure equipment, and airflow can only enter but not exit; the laboratory's cleanliness, ventilation system, and disinfection and sterilization have extremely high requirements. If the conditions are not met for testing, virus leakage is likely to occur, making the laboratory a source of contamination.

[0010] The large-scale preventive screening mechanism currently mainly measures body temperature and CT chest X-ray (for the new coronavirus). Since the human body's defense mechanism against viruses is the change in body temperature, the current effective group screening for influenza viruses is to measure body temperature. From a technical point of view, measuring body temperature can roughly screen suspected patients, but its accuracy is very low. This is because through the differential detection of temperature, a large number of non-specific templates are all classified as the type you want to detect. The problem is that as long as there is a fever, it is considered a suspected patient. You can imagine how much distortion the data detected in this way is in a very large population. If we really find a patient in this detection method, he or she has generally entered the onset period, and the 0-24 days of incubation period before the onset period caused the infection to the surrounding people to be completely uncontrollable; similarly, CT chest X-ray is also a check for suspected cases when the patient is in the onset period, and this also includes the situation of non-specific lesions. Therefore, measuring body temperature and CT chest X-ray can only make a suspected case determination during the onset period, which is ineffective for most people with the virus in the 0-24 days incubation period. Summary of the invention

[0011] The technical problem to be solved by the present invention is that the PCR detection method for coronavirus in the prior art is a fine screening method, which has very high requirements on the testing environment, equipment, and professional level of personnel. Although the accuracy is very high, the above strict technical requirements are destined to its low efficiency and high cost in large-scale clinical rapid and low-cost screening; and in the large-scale preventive screening mechanism, the main methods are currently measuring body temperature and CT chest X-ray (for new coronavirus). Measuring body temperature can roughly screen suspected patients, but its accuracy is very low. This is because through the differential detection of temperature, a large number of non-specific templates are all classified as the types to be detected. The problem is that as long as there is a fever, it is considered a suspected patient. In a population with a very large base, the data distortion of this detection is relatively large; CT chest X-ray is also a suspicious patient who will be checked and determined when the patient is in the onset period, and this also includes the situation of non-specific lesions. Therefore, measuring body temperature and CT chest X-ray can only make suspicious determinations in the onset period, which is invalid for most people with the virus in the incubation period of 0-24 days.

[0012] The present invention provides a droplet capture device based on coherent light imaging and a rapid screening method for viral nucleic acid that solve the above-mentioned problems. The present invention proposes an effective method for large-scale initial screening of the new coronavirus, and designs a droplet capture device for conveniently and quickly capturing the droplets of the person being tested on a large scale, and for initial screening of the new coronavirus. The device of the present invention can ensure that the collected droplets are more accurate in subsequent detection without destroying the large structure of the captured droplets; the rapid screening method for viral nucleic acid based on coherent light imaging of the present invention utilizes the droplet capture device proposed above, and performs rapid detection based on coherent light imaging to lock in suspicious people.

[0013] We currently know that the new coronavirus can be transmitted during the incubation period, and it is mainly through droplets, contact, body fluids, excrement, aerosols and other collateral remains of people carrying the virus. The fastest way of transmission among them is droplets, which is also the fundamental reason why we currently require self-isolation and wearing masks.

[0014] Given the high infectivity of droplets, the amount of virus in droplets is very high. If we use a technology to capture a certain amount of it in droplets, use chemical methods to make the virus show physical changes, and then use physical technology to detect its characteristics, we can make a suspected judgment on the virus in the incubation period of humans.

[0015] According to existing experiments (1), human breathing produces droplets of less than 100um in size, while the size of the known COVID-19 spherical virus is 0.125um. According to WHO data, 0.2 ml of blood from an AIDS patient can cause infection, and this amount of blood contains no more than 1,000 HIV viruses. By analogy, a droplet group of less than 100um in size, with a unit content of 50 viruses, can carry enough virus to infect others in 0.2 ml of droplets.

[0016] Through the macroscopic analysis of the amount of virus carried by droplets above, we know that if 0.2mL of droplets are collected from one person at a time, the latent virus can be found through physical and chemical analysis and triage can be completed before the onset of the disease. At present, the reliable collection methods for pathogens of influenza viruses include nasal swabs, pharyngeal swabs, throat extracts, lung extracts, body fluids (urine, blood), excrement, etc. Droplets are lung fluids, throat fluids, saliva and synthetic fluids, and have a good characteristic composition of respiratory organ microbial molecular groups. Extracting droplets is a good and reliable method.

[0017] The present invention is achieved through the following technical solutions:

[0018] A droplet capture device based on coherent light imaging comprises a protective mask, which is worn on the face of a person being tested and is tightly combined with the face; further comprises a capture box used in conjunction with the protective mask, which is movably mounted on the protective mask; a capture body is provided on one side of the capture box, and the capture box and the capture body are in a rightward T-shape; the capture body is a cavity with an opening on one side, and a capture sheet is vertically provided in the cavity;

[0019] When the person being tested wears the droplet capturing device, the capturing body is combined with the mouth of the person being tested. When the person being tested speaks or exhales, the capturing piece captures the droplets in the mouth of the person being tested.

[0020] The present invention is a droplet capture device based on coherent light imaging, which is used to quickly capture the droplets of each person in the crowd. The device is a disposable masked mouth breathing droplet capturer that is easy to produce and use. It is used completely in a physical way, one for each person, and is not reused. After the capturer captures the droplets of each person, it is immediately sent to an online special testing machine, and the screening of specific viruses is automatically completed within 5 minutes. The basic warning value is 1000 viral RNAs or less. It can be confirmed that most patients with this order of magnitude of virus are still in the non-morbid incubation period. The present invention has a simple and reasonable structure, which is used to conveniently and quickly capture the droplets of the person being tested on a large scale, and is used for the initial screening of patients with new coronavirus; at the same time, the cost is not high, which is conducive to large-scale promotion and use.

[0021] Preferably, the capture sheet is based on a polyimide film with a thickness of 125um. Since the polyimide film has stable chemical properties, good mechanical properties, is not easily stretched and deformed, and has excellent temperature and dielectric properties, it is ideal for transporting viral RNA and chemical reactions as a substrate.

[0022] Preferably, a plurality of pits are pressed on the capture sheet by molding, and the pits are evenly distributed in an array.

[0023] Preferably, the diameter of the pit is 100 um and the depth is 90 um; the interval between adjacent pits is 100 um.

[0024] Preferably, the surface of the pit is provided with an enzyme coating.

[0025] Preferably, the size range of the capture sheet is (2mm*2mm, 60mm*60mm).

[0026] Preferably, it also includes a protective cover, which is made of plastic material. The protective cover is fitted on the capture body in a manner that matches the size of the capture body to protect the safety of collecting droplet samples in the capture body.

[0027] On the other hand, the present invention also provides a method for rapid screening of viral nucleic acid based on coherent light imaging, which method uses the above-mentioned droplet capture device based on coherent light imaging, and the method comprises the following steps:

[0028] Step 1, droplet collection: the subject wears the droplet capture device based on coherent light imaging, and the droplet capture device collects the droplets in the mouth of the subject;

[0029] Step 2, preparation: After the collection is completed, the capture sheet on the droplet capture device is immediately placed in the on-site coherent light comprehensive tester for chemical reaction of the specimen sheet, and the droplets and the enzyme coating in the pits of the capture sheet (a specific display enzyme coating for the virus has been prepared in advance in each small pit on the polyimide film capture sheet) produce specific display (macromolecular cluster display);

[0030] Step 3, testing and judgment: Use coherent laser technology to irradiate the specimen, track and irradiate the droplets in all the pits from the early stage of the chemical reaction, and image the droplets. The imaging resolution is 50um in the longitude and latitude directions and 50um in the depth direction. Find the virus molecule cluster to be detected. Since the volume of each pit filled with droplets is 0.5mL, the virus participating in the reaction and reaching the detection requirement of more than 1,000 can be achieved. Therefore, each small pit becomes an independent comparison "test tube". Up to 529 "micro-test tube" groups, coupled with the use of coherent laser technology in depth tomography, are fully capable of finding the virus molecule cluster; and use computer system science to analyze and determine whether the number of viruses in the body of the person being tested has reached the incubation period standard;

[0031] Step 4: Based on steps 1 to 3, execute the next test subject in a loop to conduct rapid viral nucleic acid screening.

[0032] Furthermore, the droplet capture device based on coherent light imaging is installed in a specific negative pressure mobile room. The person being tested enters the negative pressure mobile room and wears the droplet capture device. The test is performed by speaking or exhaling within a specified time. For example, the person being tested can say a specific sentence (such as counting, etc.) for 1 minute to complete the droplet capture.

[0033] The present invention is based on the rapid screening method of viral nucleic acid for coherent light imaging. The entire sampling-preparation-testing-judgment cycle time is 3 minutes (or shorter). The personnel used for on-site detection are one person with general basic health knowledge and one computer operator. The detection equipment is installed in a specific negative pressure mobile room with a size of no more than 2000mm*2000mm*3000mm; the detection equipment is calculated based on completing a detection once in 3 minutes. It is installed in the personnel flow area and can detect 20 people per hour; in addition, because it is a mobile detection, it can realize 24-hour uninterrupted detection of the mobile population. Based on the key screening of 1 million people, 500 devices are set in a key area, and 1000000 / (24*20*500)=4 days are completed, which can basically ensure that possible latent patients are detected before they become ill.

[0034] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0035] 1. The droplet capture device based on coherent light imaging of the present invention has a simple and reasonable structure, and is used to conveniently and quickly capture the droplets of the detected person on a large scale, and is used for the initial screening of patients with new coronavirus; at the same time, the cost is not high, which is conducive to large-scale promotion and use;

[0036] 2. The droplet capture device based on coherent light imaging and the rapid screening method for viral nucleic acid based on coherent light imaging of the present invention have a cycle time of 3 minutes (or shorter) for the entire sampling-preparation-testing-judgment, and the personnel used for on-site detection are one person with general basic health knowledge and one computer operator, rather than professional medical personnel; the detection equipment is installed in a specific negative pressure mobile room, and the detection equipment completes a detection calculation based on 3 minutes. It is installed in the personnel flow area and can detect 20 people per hour; in addition, since it is a mobile detection, it can realize 24-hour uninterrupted detection of the mobile population. Based on the key screening of the previous 1 million people, 500 devices are set in a key area, and 1000000 / (24*20*500)=4 days are completed, which can basically ensure that possible latent patients are detected before they become ill; it is suitable for the preliminary screening of latent patients with new coronavirus in the latent period of a large population, and at the same time, the accuracy is higher than temperature screening, and it is faster than CT chest X-ray and saves costs. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] The drawings described herein are used to provide a further understanding of the embodiments of the present invention, constitute a part of this application, and do not constitute a limitation of the embodiments of the present invention. In the drawings:

[0038] Figure 1 The figure is a layout diagram of a prior art PCR laboratory.

[0039] Figure 2 This is a schematic diagram of the structure of the rapid RNA screening method using coherent light imaging technology of the present invention.

[0040] Figure 3 The schematic diagram is a structural diagram of the droplet capturing device of the present invention when used by a person being tested.

[0041] Figure 4 The structure of the droplet capture device of the present invention is shown in FIG. Figure 1 .

[0042] Figure 5 The structure of the droplet capture device of the present invention is shown in FIG. Figure 2 .

[0043] Figure 6 It is a schematic diagram of the structure of the capture piece of the droplet capture device of the present invention.

[0044] Figure 7 It is a schematic diagram of the side of the capture piece of the droplet capture device of the present invention and the droplets flying out of the mouth of the person being tested.

[0045] Marks and corresponding parts names in the attached drawings:

[0046] 1-protective mask, 2-capture box, 3-capture body, 4-capture sheet, 5-protective cover, 6-pit. DETAILED DESCRIPTION

[0047] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments and drawings. The exemplary embodiments of the present invention and their description are only used to explain the present invention and are not intended to limit the present invention.

[0048] Example 1

[0049] like Figures 1 to 7 As shown, the droplet capturing device based on coherent light imaging of the present invention comprises a protective mask 1, which is worn on the face of the person being detected and is tightly combined with the face; it also comprises a capturing box 2 used in conjunction with the protective mask 1, and the capturing box 2 is movably mounted on the protective mask 1; a capturing body 3 is provided on one side of the capturing box 2, and the capturing box 2 and the capturing body 3 are in a rightward T-shape; the capturing body 3 is a cavity with an opening on one side, and a capturing sheet 4 is vertically provided in the cavity;

[0050] When the subject wears the droplet capturing device, the capturing body 3 is combined with the subject's mouth. When the subject speaks or exhales, the capturing sheet 4 captures the droplets in the subject's mouth.

[0051] In this embodiment, the capture sheet 4 is based on a polyimide film with a thickness of 125um. Since the polyimide film has stable chemical properties, good mechanical properties, is not easy to stretch and deform, and has excellent temperature and dielectric properties, it is ideal for the transport and chemical reaction of viral RNA.

[0052] In this embodiment, a plurality of pits 6 are pressed on the capture sheet 4 by molding, and the pits 6 are evenly distributed in an array.

[0053] In this embodiment, the diameter of the pit 6 is 100 um and the depth is 90 um; the interval between adjacent pits 6 is 100 um.

[0054] In this embodiment, an enzyme coating is provided on the surface of the pit 6 .

[0055] In this embodiment, the size of the capture sheet 4 is in the range of (2mm*2mm, 60mm*60mm).

[0056] In this embodiment, a protective cover 5 is further included. The material of the protective cover 5 is plastic material. The protective cover 5 is buckled on the capture body 3 with a size that matches the size to protect the safety of collecting droplet samples in the capture body 3.

[0057] The droplet capture device based on coherent light imaging of the present invention is used to quickly capture the droplets of each person in a crowd. The device is a disposable, mouth-shielded, breath-type droplet capturer that is easy to produce and use. It is used completely in a physical manner, one for each person, and is not reused. After the capturer captures the droplets of each person, it is immediately sent to an online special testing machine, and the screening of specific viruses is automatically completed within 5 minutes. The basic warning value is 1,000 viral RNAs or less. It can be confirmed that most patients with this order of magnitude of virus are still in the latent period of non-onset.

[0058] The invention has a simple and reasonable structure, and is used to conveniently and quickly capture the droplets of the person being tested on a large scale, and is used for the initial screening of patients with the new coronavirus; at the same time, the cost is not high, which is conducive to large-scale promotion and use.

[0059] Example 2

[0060] like Figures 1 to 7 As shown, the difference between this embodiment and embodiment 1 is that the rapid screening method for viral nucleic acid based on coherent light imaging uses the droplet capture device based on coherent light imaging in the above embodiment 1, and the method includes the following steps:

[0061] Step 1, droplet collection: the subject wears the droplet capture device based on coherent light imaging described in Implementation 1, and the droplet capture device collects the droplets in the mouth of the subject;

[0062] Step 2, preparation: After the collection is completed, the capture sheet on the droplet capture device is immediately placed in the on-site coherent light comprehensive tester for chemical reaction of the specimen sheet, and the droplets and the enzyme coating in the pits of the capture sheet (a specific display enzyme coating for the virus has been prepared in advance in each small pit on the polyimide film capture sheet) produce specific display (macromolecular cluster display);

[0063] Step 3, testing and judgment: Use coherent laser technology to irradiate the specimen, track and irradiate the droplets in all the pits from the early stage of the chemical reaction, and image the droplets. The imaging resolution is 50um in the longitude and latitude directions and 50um in the depth direction. Find the virus molecule cluster to be detected. Since the volume of each pit filled with droplets is 0.5mL, the virus participating in the reaction and reaching the detection requirement of more than 1,000 can be achieved. Therefore, each small pit becomes an independent comparison "test tube". Up to 529 "micro-test tube" groups, coupled with the use of coherent laser technology in depth tomography, are fully capable of finding the virus molecule cluster; and use computer system science to analyze and determine whether the number of viruses in the body of the person being tested has reached the incubation period standard;

[0064] Step 4: Based on steps 1 to 3, execute the next test subject in a loop to conduct rapid viral nucleic acid screening.

[0065] Specifically, the droplet capture device based on coherent light imaging is installed in a specific negative pressure mobile room. The person being tested enters the negative pressure mobile room and wears the droplet capture device. The test is performed by speaking or exhaling within a specified time. For example, the person being tested can say a specific sentence (such as counting, etc.) for 1 minute to complete the droplet capture.

[0066] Specifically, the preparation process of the capture sheet in the droplet capture device is as follows:

[0067] Step 001, using polyimide film as substrate and selecting 125um thick transparent material to make a core droplet capture sheet;

[0068] Step 002, using a molding method to press the polyimide film into pits with a diameter of 100 um and a depth of 90 um, and press them in groups with an interval of 100 um; the prepared polyimide film is cut into a rectangular sheet of 7 mm*7 mm;

[0069] Step 003: Design and manufacture a mask-like device (i.e., a protective mask) using meltblown cloth. A capture box and a capture body with a capture sheet can be fixedly placed directly in front of the mouth. The protective mask has the protection capability of a KN100 mask, but its purpose is to prevent droplets in the mouth of the test person from spreading into the air.

[0070] Figure 6 It is a schematic diagram of the structure of the capture piece of the droplet capture device of the present invention, Figure 6 The number of pits in the figure is only for illustration and is not the actual number of pits. Figure 6 The ratio used is 1: 1000. In this embodiment, the number of pits is 23*23=529.

[0071] Figure 7 It is a schematic diagram of the side of the capture piece of the droplet capture device of the present invention and the droplets flying out of the mouth of the person being tested.

[0072] Figure 2 The schematic diagram of the structure of the rapid RNA screening method (including the sample collection area) using the coherent light imaging technology of the present invention is shown in FIG. 2 Real-time negative pressure testing, completing a sampling test in 3 minutes.

[0073] The present invention is based on the rapid screening method of viral nucleic acid based on coherent light imaging. The entire sampling-preparation-testing-judgment cycle time is 3 minutes (or shorter). The personnel used for on-site detection are one person with general basic health knowledge and one computer operator. The detection equipment is installed in a specific negative pressure mobile room with a size not greater than 2000mm*2000mm*3000mm; the detection equipment is calculated based on a detection calculation of 3 minutes, installed in the personnel flow area, and can detect 20 people per hour; in addition, because it is a mobile detection, it can realize 24-hour uninterrupted detection of the mobile population. Based on the key screening of the previous 1 million people, 500 devices are set in a key area, 1000000 / (24*20*500)=4 days to complete, which can basically ensure that possible latent patients are detected before they become ill. The method of the present invention is suitable for the preliminary screening of latent patients of the new coronavirus in the latent period of a large population, and at the same time, the accuracy is higher than that of temperature screening, and it is faster than CT chest radiography and saves costs.

[0074] The specific implementation methods described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above description is only a specific implementation method of the present invention and is not intended to limit the scope of protection of the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A droplet capturing device based on coherent light imaging, comprising a protective mask (1), wherein the protective mask (1) is worn on the face of a person being detected and is tightly combined with the face; characterized in that: It also comprises a capture box (2) for use with the protective mask (1), the capture box (2) being movably mounted on the protective mask (1); a capture body (3) is provided on one side of the capture box (2), the capture box (2) and the capture body (3) forming a T-shape facing rightwards; the capture body (3) is a cavity with an opening on one side, and a capture sheet (4) is vertically provided in the cavity; The subject wears the droplet capturing device, and the capturing body (3) is combined with the mouth of the subject. When the subject speaks or exhales, the capturing sheet (4) captures the droplets in the mouth of the subject. The capture sheet (4) has a polyimide film as a substrate and has a thickness of 125 μm; The capture sheet (4) is provided with a plurality of pits (6) by molding, and the pits (6) are evenly distributed in an array; The diameter of the pit (6) is 100 um and the depth is 90 um; the interval between adjacent pits (6) is 100 um; The surface of the pit (6) is provided with an enzyme coating; The droplet capture device is used for initial screening of the new coronavirus.

2. The droplet capturing device based on coherent light imaging according to claim 1 is characterized in that: The size of the capture piece (4) is greater than or equal to 2 mm*2 mm and less than or equal to 60 mm*60 mm.

3. The droplet capturing device based on coherent light imaging according to claim 1 is characterized in that: It also comprises a protective cover (5), the protective cover (5) being buckled onto the capturing body (3) with a matching size.

4. A rapid screening method for viral nucleic acid based on coherent light imaging, characterized in that: The method uses the droplet capturing device based on coherent light imaging as described in any one of claims 1 to 3, and the method comprises the following steps: Step 1, droplet collection: the subject wears the droplet capture device based on coherent light imaging as described in any one of claims 1 to 3, and the droplet capture device collects the droplets in the mouth of the subject; Step 2, preparation: After the collection is completed, the capture piece on the droplet capture device is immediately placed in the on-site coherent light comprehensive tester to carry out a chemical reaction of the specimen piece, and the droplets and the enzyme coating in the pits of the capture piece produce specific display; Step 3, testing and judgment: Use coherent laser technology to irradiate the specimen, track the irradiation imaging from the early stage of the chemical reaction to the droplets in all pits, with an imaging resolution of 50um in the longitude and latitude directions and 50um in the depth direction, find the virus molecule cluster to be tested, and use computer system science to analyze it to determine whether the number of viruses in the body of the person being tested has reached the incubation period standard; Step 4: Based on steps 1 to 3, execute the next test subject in a loop to conduct rapid viral nucleic acid screening.

5. The method for rapid screening of viral nucleic acid based on coherent light imaging according to claim 4, characterized in that: The droplet capture device based on coherent light imaging is installed in a negative pressure mobile room, the size of which is no larger than 2000mm*2000mm*3000mm; the person being tested enters the negative pressure mobile room and wears the droplet capture device, and is tested by speaking or exhaling within a specified time.

Images